Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

QR Code

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

BackgroundData on the use of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation are limited. The current study aimed to assess the efficacy of ICIs in EGFR-mutant advanced NSCLC and explore the relevant in...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Tian Tian, Min Yu, Juan Li, Maoqiong Jiang, Daiyuan Ma, Shubin Tang, Zhiyu Lin, Lin Chen, Youling Gong, Jiang Zhu, Qiang Zhou, Meijuan Huang, You Lu
Format:	article
Langue:	EN
Publié:	Frontiers Media S.A. 2021
Sujets:	non–small cell lung cancer immune checkpoint inhibitor tyrosine kinase inhibitor epidermal growth factor receptor resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/69a13cda47364735a4dda48c6d0895f8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
par: Gan J, et autres
Publié: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
par: Wen M, et autres
Publié: (2018)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
par: Svetlana V. Odintsova, et autres
Publié: (2020)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
par: Nathaniel Wiest, et autres
Publié: (2021)

Management of VEGFR-Targeted TKI for Thyroid Cancer
par: Tomohiro Enokida, et autres
Publié: (2021)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
par: Liesbeth M. Hondelink, MD, et autres
Publié: (2021)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
par: Facchinetti F, et autres
Publié: (2019)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
par: Michela Verzè, et autres
Publié: (2021)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
par: Yukari Tsubata, et autres
Publié: (2021)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
par: Lee CS, et autres
Publié: (2020)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
par: Brazel D, et autres
Publié: (2021)

Oligoprogression in Non-Small Cell Lung Cancer
par: Daijiro Harada, et autres
Publié: (2021)

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
par: Ling-Ling Kong, et autres
Publié: (2017)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
par: Sergey V. Goryaynov
Publié: (2021)

Targeted Therapies in Cancer: To Be or Not to Be, Selective
par: Skye Montoya, et autres
Publié: (2021)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
par: Paula Aldaz, et autres
Publié: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
par: Sánchez-Herrero Estela, et autres
Publié: (2020)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
par: Syahruddin E, et autres
Publié: (2018)

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
par: Ana Podolski-Renić, et autres
Publié: (2021)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
par: Santarpia M, et autres
Publié: (2017)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
par: Cristina Minnelli, et autres
Publié: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
par: Akiko Takahashi, et autres
Publié: (2018)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
par: Elisabete Cruz Da Silva, et autres
Publié: (2021)

Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth
par: YingYing He, et autres
Publié: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
par: Whitney E. Lewis, PharmD, et autres
Publié: (2021)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
par: Katsuhiro Yoshimura, MD, PhD, et autres
Publié: (2021)

Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
par: Yu-Mu Chen, et autres
Publié: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
par: Alexey A. Bogdanov, et autres
Publié: (2021)

Diffuse scaly erythematous plaques in patient taking poziotinib
par: Reid Oldenburg, MD, PhD, et autres
Publié: (2022)

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
par: Archibald M, et autres
Publié: (2016)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
par: Sareshma Sudhesh Dev, et autres
Publié: (2021)

SYNTHESIS AND SAR STRATEGY OF THIAZOLIDINEDIONE: A NOVEL APPROACH FOR CANCER TREATMENT
par: Rashid,Mohammad, et autres
Publié: (2020)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
par: Wang J, et autres
Publié: (2021)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
par: Yang W, et autres
Publié: (2020)

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
par: ZHU Kuikui, et autres
Publié: (2021)

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
par: Josette Kamel, BA, et autres
Publié: (2021)

Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
par: Chunying Peng, et autres
Publié: (2021)

The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice
par: Zhongju Lu, et autres
Publié: (2021)

The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
par: Kamil D. Kaplanov
Publié: (2021)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
par: Weiguo Gu, et autres
Publié: (2021)